CytoDyn partners with Natera to study ctDNA response in metastatic colorectal cancer trial

Natera, Inc.
CYTODYN INC

Natera, Inc.

NTRA

0.00

CYTODYN INC

CYDY

0.00
  • CytoDyn entered a strategic collaboration with Natera to use ctDNA data to support its metastatic colorectal cancer development program for leronlimab.
  • Natera will test samples from the CLOVER Phase 2 study using its Signatera assay to track ctDNA dynamics and molecular response signals.
  • Natera will also deliver real-world data analyses from its oncology database to inform trial design, biomarker-driven patient selection, and translational research.
  • The work follows completion of enrollment in CLOVER, which evaluates leronlimab with TAS-102 and bevacizumab in previously treated metastatic colorectal cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.